CTSZ and posterior cortical atrophy: Given the strong association of high CTSZ expression with both enhanced tumor aggressiveness and an immunosuppressive TME in PCa, CTSZ may serve not only as a prognostic biomarker but also as a therapeutic target within a theragnostic framework.